Balyasny Asset Management
AKRO

Balyasny Asset Management’s Akero Therapeutics AKRO Stock Holding History

Balyasny Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-96,371
Closed -$5.14M – 2866
2025
Q2 		$5.14M Buy
+96,371
New +$4.38M 0.01% 1279
2025
Q1 		– Sell
-649,134
Closed -$18.1M – 2749
2024
Q4 		$18.1M Buy
+649,134
New +$19.7M 0.03% 715
2024
Q1 		– Sell
-198,271
Closed -$4.63M – 2572
2023
Q4 		$4.63M Buy
198,271
+158,988
+405% +$3.14M 0.01% 1143
2023
Q3 		$1.99M Sell
39,283
-38,250
-49% -$1.78M ﹤0.01% 1374
2023
Q2 		$3.62M Buy
+77,533
New +$3.55M 0.01% 1174

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's AKRO Position: Q3 2025 in Review

Balyasny Asset Management sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 96,371 shares — an estimated $5.14M sold.

Balyasny Asset Management first reported a position in AKRO in Q2 2023 and held it in 5 quarters. The position peaked at $18.1M in Q4 2024. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Balyasny Asset Management reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 96,371 Akero Therapeutics shares in Q3 2025, an estimated $5.14M.
  • Balyasny Asset Management first reported a position in Akero Therapeutics in Q2 2023 and held it in 5 quarters.
  • Balyasny Asset Management's Akero Therapeutics position peaked at $18.1M in Q4 2024.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.